Report Thumbnail
Product Code DB091210648ATI
Published Date 2024/2/1
Data Bridge Market Research
English565 PagesMiddle East / Africa

MEA Pharmacogenetics Testing in PsychiatryDepression Market ‐ MedicalDevice_MedTech Market


Report Thumbnail
Product Code DB091210648ATI◆The Feb 2026 edition is also likely available. We will check with the publisher immediately.
Published Date 2024/2/1
Data Bridge Market Research
English 565 PagesMiddle East / Africa

MEA Pharmacogenetics Testing in PsychiatryDepression Market ‐ MedicalDevice_MedTech Market


Abstract

Summary

The Middle East and Africa pharmacogenetics testing in psychiatry/depression market is expected to reach USD 59.30 thousand by 2031 from USD 132.56 thousand in 2023, growing with a CAGR of 8.0 % in the forecast period of 2024 to 2034. Market Segmentation Middle East and Africa Pharmacogenetics Testing in Psychiatry/Depression Market, By Type (Anxiety, Mood Disorders, Depression, Bipolar Disorders, Psychotic Disorders, and Eating Disorders), Test Type (Whole Genome Sequencing and Chromosomal Array-Based Tests), Patient Type (Child, Adults, and Geriatric), Gene Type (CYP2C19, CYP2C9 and VKORC1, CYP2D6, HLA-B, HTR2A/C, HLA-A, CYP3A4, SLC6A4, MTHFR, COMT, and Others), Products (Instruments, Consumables, and Software and Services), End User (Hospitals and Clinics, Diagnostics Laboratories, Academic and Research Institutes, and Others), Distribution Channel (Direct Tender, Third Party Distribution, Hospital Pharmacy, and Others), Country (South Africa, Saudi Arabia, UAE, Egypt, Israel, and Rest of Middle East and Africa) - Industry Trends and Forecast to 2031 Overview of Middle East and Africa Pharmacogenetics Testing in Psychiatry/Depression Market Dynamics Driver • Rising number of population suffering from depressive disorder Restraint • Insufficient clinical validation Opportunity • Advancements in genetic testing Market Players Some of the major market players operating in the Middle East and Africa pharmacogenetics testing in psychiatry/depression market are listed below: • ThermoFisher Scientific Inc. (U.S.) • Illumina Inc. (U.S.) • Myriad Genetics Inc. (U.S.) • Sonic Healthcare Limited (Australia) • QIAGEN (Germany) • AB-BIOTICS S.A. (Spain) • BiogeniQ Inc. (Canada) • Castle Bioscience Inc. (U.S.) • Coriell Life Sciences (U.S.) • Dynamic DNA Laboratories (U.S.) • Eurofins Scientific (Luxembourg) • Genelex (U.S.) • Genewiz (U.S.) • Genomind Inc. (U.S.) • GenXys (Canada) • HealthSpek (U.S.) • HudsonAlpha (U.S.) • MD Labs (U.S.) • ONEOME LLC (U.S.) • PacBio (U.S.)

Table of Contents

  • 1 INTRODUCTION 62

    • 1.1 OBJECTIVES OF THE STUDY 62
    • 1.2 MARKET DEFINITION 62
    • 1.3 OVERVIEW OF MIDDLE EAST AND AFRICA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET 62
    • 1.4 CURRENCY AND PRICING 64
    • 1.5 LIMITATIONS 64
    • 1.6 MARKETS COVERED 65

  • 2 MARKET SEGMENTATION 70

    • 2.1 MARKETS COVERED 70
    • 2.2 GEOGRAPHICAL SCOPE 71
    • 2.3 YEARS CONSIDERED FOR THE STUDY 72
    • 2.4 DBMR TRIPOD DATA VALIDATION MODEL 73
    • 2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 76
    • 2.6 MULTIVARIATE MODELLING 77
    • 2.7 MARKET END USER COVERAGE GRID 78
    • 2.8 TYPE LIFELINE CURVE 79
    • 2.9 DBMR MARKET POSITION GRID 80
    • 2.10 VENDOR SHARE ANALYSIS 82
    • 2.11 SECONDARY SOURCES 83
    • 2.12 ASSUMPTIONS 83

  • 3 EXECUTIVE SUMMARY 84

  • 4 PREMIUM INSIGHT 88

    • 4.1 PESTAL ANALYSIS 90
    • 4.2 PORTERS FIVE FORCES 91

  • 5 INDUSTRIAL INSIGHTS 92

  • 6 MIDDLE EAST AND AFRICA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, REGULATIONS 94

    • 6.1 U.S 94
    • 6.2 EUROPEAN UNION (EU) 95
    • 6.3 FRANCE 95
    • 6.4 AUSTRALIA 95
    • 6.5 SOUTH KOREA 95

  • 7 MARKET OVERVIEW 96

    • 7.1 DRIVERS 98
      • 7.1.1 RISING NUMBER OF POPULATION SUFFERING FROM DEPRESSIVE DISORDER 98
      • 7.1.2 INITIATIVES TAKEN BY MANUFACTURERS DUE TO GENETIC VARIABILITY 98
      • 7.1.3 GROWING BIOTECHNOLOGY SECTOR ALONG WITH RISING HEALTHCARE EXPENDITURE 99
      • 7.1.4 INCREASING INTEREST FOR PERSONALIZED AND PRECISION MEDICATION 99
    • 7.2 RESTRAINTS 100
      • 7.2.1 INSUFFICIENT CLINICAL VALIDATION 100
      • 7.2.2 STIGMA AND PERCEPTION FOR MENTAL HEALTH 101
      • 7.2.3 LACK OF REIMBURSEMENT 101
    • 7.3 OPPORTUNITIES 102
      • 7.3.1 ADVANCEMENTS IN GENETIC TESTING 102
      • 7.3.2 EMERGING START-UPS BRANCHES INNOVATION 103
      • 7.3.3 REDUCED HEALTHCARE COSTS THROUGH THE IMPLEMENTATION OF COST-SAVING MEASURES 103
    • 7.4 CHALLENGES 104
      • 7.4.1 RISING CONCERN REGARDING DATA PRIVACY AND SECURITY 104
      • 7.4.2 SHORTAGE OF SKILLED HEALTHCARE PROFESSIONALS 105

  • 8 MIDDLE EAST AND AFRICA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT 106

    • 8.1 OVERVIEW 107
    • 8.2 CONSUMABLES 111
    • 8.3 INSTRUMENTS 113
    • 8.4 SOFTWARE AND SERVICES 114

  • 9 MIDDLE EAST AND AFRICA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE 115

    • 9.1 OVERVIEW 116
    • 9.2 WHOLE GENOME SEQUENCING 119
    • 9.3 CHROMOSOMAL ARRAY BASED TESTS 123

  • 10 MIDDLE EAST AND AFRICA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE 125

    • 10.1 OVERVIEW 126
    • 10.2 ANXIETY 130
    • 10.3 DEPRESSION 131
    • 10.4 MOOD DISORDERS 132
    • 10.5 BIPOLAR DISORDERS 133
    • 10.6 EATING DISORDERS 134
    • 10.7 PSYCHOTIC DISORDERS 135

  • 11 MIDDLE EAST AND AFRICA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GENE TYPE 136

    • 11.1 OVERVIEW 137
    • 11.2 CYP2C19 141
    • 11.3 CYP2C9 AND VKORC1 142
    • 11.4 CYP2D6 143
    • 11.5 HLA-B 144
    • 11.6 HTR2A/C 145
    • 11.7 HLA-A 146
    • 11.8 CYP3A4 147
    • 11.9 SLC6A4 148
    • 11.10 MTHFR 149
    • 11.11 COMT 150
    • 11.12 OTHERS 151

  • 12 MIDDLE EAST AND AFRICA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PATIENT TYPE 152

    • 12.1 OVERVIEW 153
    • 12.2 ADULT 157
    • 12.3 GERIATRIC 158
    • 12.4 CHILD 159

  • 13 MIDDLE EAST AND AFRICA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER 160

    • 13.1 OVERVIEW 161
    • 13.2 HOSPITAL AND CLINICS 164
    • 13.3 DIAGNOSTICS LABORATORIES 166
    • 13.4 ACADEMIC AND RESEARCH INSTITUTES 167
    • 13.5 OTHERS 168

  • 14 MIDDLE EAST AND AFRICA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL 169

    • 14.1 OVERVIEW 170
    • 14.2 DIRECT TENDER 174
    • 14.3 THIRD PARTY DISTRIBUTION 175
    • 14.4 HOSPITAL PHARMACY 176
    • 14.5 OTHERS 177

  • 15 MIDDLE EAST AND AFRICA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION 178

    • 15.5 MIDDLE EAST AND AFRICA 436
      • 15.5.1 SOUTH AFRICA 443
      • 15.5.2 SAUDI ARABIA 450
      • 15.5.3 U.A.E 456
      • 15.5.4 ISRAEL 462
      • 15.5.5 EGYPT 469
      • 15.5.6 REST OF MIDDLE EAST AND AFRICA 476

  • 16 MIDDLE EAST AND AFRICA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET: COMPANY LANDSCAPE 507

    • 16.1 COMPANY SHARE ANALYSIS: MIDDLE EAST AND AFRICA 507

  • 17 SWOT ANALYSIS 511

  • 18 COMPANY PROFILES 512

    • 18.1 THERMO FISHER SCIENTIFIC INC 512
      • 18.1.1 COMPANY SNAPSHOT 512
      • 18.1.2 RECENT FINANCIALS 513
      • 18.1.3 COMPANY SHARE ANALYSIS 513
      • 18.1.4 PRODUCT PORTFOLIO 514
      • 18.1.5 RECENT DEVELOPMENT 516
    • 18.2 ILLUMINA, INC 517
      • 18.2.1 COMPANY SNAPSHOT 517
      • 18.2.2 REVENUE ANALYSIS 517
      • 18.2.3 COMPANY SHARE ANALYSIS 518
      • 18.2.4 PRODUCT PORTFOLIO 518
      • 18.2.5 RECENT DEVELOPMENTS 519
    • 18.3 MYRIAD GENETICS, INC 520
      • 18.3.1 COMPANY SNAPSHOT 520
      • 18.3.2 REVENUE ANALYSIS 520
      • 18.3.3 COMPANY SHARE ANALYSIS 521
      • 18.3.4 PRODUCT PORTFOLIO 521
      • 18.3.5 RECENT DEVELOPMENTS 522
    • 18.4 SONIC HEALTHCARE LIMITED 523
      • 18.4.1 COMPANY SNAPSHOT 523
      • 18.4.2 REVENUE ANALYSIS 523
      • 18.4.3 COMPANY SHARE ANALYSIS 524
      • 18.4.4 PRODUCT PORTFOLIO 524
      • 18.4.5 RECENT DEVELOPMENT 524
    • 18.5 QIAGEN 525
      • 18.5.1 COMPANY SNAPSHOT 525
      • 18.5.2 REVENUE ANALYSIS 525
      • 18.5.3 COMPANY SHARE ANALYSIS 526
      • 18.5.4 PRODUCT PORTFOLIO 526
      • 18.5.5 RECENT DEVELOPMENTS 527
    • 18.6 AB-BIOTICS, S.A 529
      • 18.6.1 COMPANY SNAPSHOT 529
      • 18.6.2 PRODUCT PORTFOLIO 529
      • 18.6.3 RECENT DEVELOPMENTS 530
    • 18.7 BIOGENIQ INC 531
      • 18.7.1 COMPANY SNAPSHOT 531
      • 18.7.2 PRODUCT PORTFOLIO 531
      • 18.7.3 RECENT DEVELOPMENT 532
    • 18.8 CASTLE BIOSCIENCE, INC 533
      • 18.8.1 COMPANY SNAPSHOT 533
      • 18.8.2 REVENUE ANALYSIS 533
      • 18.8.3 PRODUCT PORTFOLIO 534
      • 18.8.4 RECENT DEVELOPMENTS 534
    • 18.9 CORIELL LIFE SCIENCES 535
      • 18.9.1 COMPANY SNAPSHOT 535
      • 18.9.2 PRODUCT PORTFOLIO 535
      • 18.9.3 RECENT DEVELOPMENTS 535
    • 18.10 DYNAMIC DNA LABORATORIES 537
      • 18.10.1 COMPANY SNAPSHOT 537
      • 18.10.2 PRODUCT PORTFOLIO 537
      • 18.10.3 RECENT DEVELOPMENT 537
    • 18.11 EUROFINS SCIENTIFIC 539
      • 18.11.1 COMPANY SNAPSHOT 539
      • 18.11.2 REVENUE ANALYSIS 540
      • 18.11.3 PRODUCT PORTFOLIO 540
      • 18.11.4 RECENT DEVELOPMENTS 541
    • 18.12 GENELEX (SUBSIADIARY OF INVITAE CORPORATION.) 542
      • 18.12.1 COMPANY SNAPSHOT 542
      • 18.12.2 REVENUE ANALYSIS 542
      • 18.12.3 PRODUCT PORTFOLIO 543
      • 18.12.4 RECENT DEVELOPMENT 543
    • 18.13 GENEWIZ (PART OF AZENTA LIFE SCIENCES) 544
      • 18.13.1 COMPANY SNAPSHOT 544
      • 18.13.2 REVENUE ANALYSIS 544
      • 18.13.3 PRODUCT PORTFOLIO 545
      • 18.13.4 RECENT DEVELOPMENT 545
    • 18.14 GENOMIND, INC 546
      • 18.14.1 COMPANY SNAPSHOT 546
      • 18.14.2 PRODUCT PORTFOLIO 546
      • 18.14.3 RECENT DEVELOPMENTS 547
    • 18.15 GENXYS 548
      • 18.15.1 COMPANY SNAPSHOT 548
      • 18.15.2 PRODUCT PORTFOLIO 548
      • 18.15.3 RECENT DEVELOPMENTS 549
    • 18.16 HEALTHSPEK 551
      • 18.16.1 COMPANY SNAPSHOT 551
      • 18.16.2 PRODUCT PORTFOLIO 551
      • 18.16.3 RECENT DEVELOPMENT 551
    • 18.17 HUDSONALPHA 552
      • 18.17.1 COMPANY SNAPSHOT 552
      • 18.17.2 PRODUCT PORTFOLIO 552
      • 18.17.3 RECENT DEVELOPMENT 553
    • 18.18 MD LABS 554
      • 18.18.1 COMPANY SNAPSHOT 554
      • 18.18.2 PRODUCT PORTFOLIO 554
      • 18.18.3 RECENT DEVELOPMENT 554
    • 18.19 ONEOME, LLC 555
      • 18.19.1 COMPANY SNAPSHOT 555
      • 18.19.2 PRODUCT PORTFOLIO 555
      • 18.19.3 RECENT DEVELOPMENTS 556
    • 18.20 PACBIO 558
      • 18.20.1 COMPANY SNAPSHOT 558
      • 18.20.2 REVENUE ANALYSIS 558
      • 18.20.3 PRODUCT PORTFOLIO 559
      • 18.20.4 RECENT DEVELOPMENTS 559

  • 19 QUESTIONNAIRE 561

  • 20 RELATED REPORTS 565

USD 3,500 or Partial Purchase
*Prices are subject to change by the publisher.
© 2026 ShareFair Inc.
MEA Pharmacogenetics Testing in PsychiatryDepression Market | MedicalDevice_MedTech Market Research Report - ShareFair Markets